Health
Dr Reddy's Wins DCGI Approval for Zytorvi in Advanced Esophageal Cancer
India's drug regulator has cleared toripalimab as a first-line immunotherapy combination for advanced esophageal squamous cell carcinoma, the drug's second indication in the country.

Dr Reddy's Laboratories has received approval from the Drugs Controller General of India (DCGI) for Zytorvi (toripalimab) in advanced esophageal squamous cell carcinoma (ESCC), the company announced on Wednesday, October 21.
The clearance covers use with cisplatin and paclitaxel as first-line treatment for adults whose ESCC is unresectable, advanced, recurrent or metastatic. It is Zytorvi's second approved use in India, after nasopharyngeal carcinoma.
The target population is significant. According to the company, ESCC makes up roughly 80 per cent of esophageal cancer cases in India. Dr Reddy's says the approval is meant to widen access to first-line immunotherapy for these patients.
Toripalimab is a monoclonal antibody that attaches to PD-1 and blocks its interaction with PD-L1 and PD-L2. That action supports T-cell activity against cancer cells.
The approval rests on the Phase 3 JUPITER-06 trial. Per the company's release, adding toripalimab to paclitaxel and cisplatin cut the risk of disease progression or death by 42 per cent versus chemotherapy alone. In the final overall-survival analysis, median survival was 17.7 months with the combination against 12.9 months with chemotherapy alone.
Dr Reddy's holds commercialisation rights to toripalimab in 21 countries under a 2023 agreement with Junshi Biosciences. Pricing and launch timelines were not part of the source details.